Application 212774
- Type
- ANDA
- Sponsor
- AUROBINDO PHARMA LTD
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | MIDODRINE HYDROCHLORIDE | MIDODRINE HYDROCHLORIDE | TABLET;ORAL | 2.5MG | No | No |
| 002 | MIDODRINE HYDROCHLORIDE | MIDODRINE HYDROCHLORIDE | TABLET;ORAL | 5MG | No | No |
| 003 | MIDODRINE HYDROCHLORIDE | MIDODRINE HYDROCHLORIDE | TABLET;ORAL | 10MG | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 0615-8382 | Midodrine Hydrochloride | Midodrine Hydrochloride | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | Current |
| 0615-8382 | Midodrine Hydrochloride | Midodrine Hydrochloride | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | Current |
| 0615-8383 | Midodrine Hydrochloride | Midodrine Hydrochloride | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | Current |
| 0615-8383 | Midodrine Hydrochloride | Midodrine Hydrochloride | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | Current |
| 0615-8384 | Midodrine Hydrochloride | Midodrine Hydrochloride | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | Current |
| 0615-8384 | Midodrine Hydrochloride | Midodrine Hydrochloride | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | Current |
| 59651-246 | Midodrine Hydrochloride | Midodrine Hydrochloride | Aurobindo Pharma Limited | ANDA | Current |
| 59651-246 | Midodrine Hydrochloride | Midodrine Hydrochloride | Aurobindo Pharma Limited | ANDA | Current |
| 59651-247 | Midodrine Hydrochloride | Midodrine Hydrochloride | Aurobindo Pharma Limited | ANDA | Current |
| 59651-247 | Midodrine Hydrochloride | Midodrine Hydrochloride | Aurobindo Pharma Limited | ANDA | Current |
| 59651-248 | Midodrine Hydrochloride | Midodrine Hydrochloride | Aurobindo Pharma Limited | ANDA | Current |
| 59651-248 | Midodrine Hydrochloride | Midodrine Hydrochloride | Aurobindo Pharma Limited | ANDA | Current |